Visiopharm Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
96
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.78M
- Investors
-
6
Visiopharm General Information
Description
Developer of digital precision pathology software designed to support researchers, diagnostics, and drug and companion diagnostics development. The company's software uses artificial intelligence and deep learning to deliver tissue data mining, precision results, standardization of tissue data, and improved productivity, enabling medical practitioners to operate on various virtual slide microscopes.
Contact Information
Website
www.visiopharm.comCorporate Office
- Agern Allé 24
- 2970 Hoersholm
- Denmark
Corporate Office
- Agern Allé 24
- 2970 Hoersholm
- Denmark
Visiopharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 10-Jan-2023 | $2.78M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 01-Sep-2020 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 23-Aug-2018 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 29-Nov-2016 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 30-Apr-2015 | $868K | $1.87M | Completed | Generating Revenue | |
| 1. Later Stage VC | 05-Oct-2007 | $997K | $997K | Completed | Generating Revenue |
Visiopharm Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| B Shares | ||||||||
| A Shares | 97,176 | $7.79 | $7.79 | 1x | $7.79 | 5.7% | ||
| Ordinary | 5,000 | $0.57 | $0.57 | 1x | $0.57 | 0.29% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Visiopharm Comparisons
Industry
Financing
Details
Visiopharm Competitors (12)
One of Visiopharm’s 12 competitors is Aiforia, a Formerly VC-backed company based in Helsinki, Finland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aiforia | Formerly VC-backed | Helsinki, Finland | ||||
| Orchard Software | Private Equity-Backed | Carmel, IN | ||||
| Ibex Medical Analytics | Venture Capital-Backed | Tel Aviv, Israel | ||||
| Kanteron Systems | Corporation | Paterna, Spain | ||||
| NovoPath | Private Equity-Backed | Bridgewater, NJ |
Visiopharm Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Visiopharm Patents
Visiopharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230122073-A1 | Medical image analysis system and method for managing medical images | Pending | 05-Mar-2020 | ||
| EP-4115387-A1 | Medical image analysis system and method for managing medical images | Pending | 05-Mar-2020 | ||
| EP-3991088-A1 | Scanning/pre-scanning quality control of slides | Pending | 28-Jun-2019 | ||
| US-20220260825-A1 | Scanning/pre-scanning quality control of slides | Active | 28-Jun-2019 | ||
| EP-3757872-A1 | Scanning/pre-scanning quality control of slides | Inactive | 28-Jun-2019 | G06T7/0012 |
Visiopharm Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Visiopharm Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BankInvest Group | Asset Manager | Minority | ||
| C. L. David Foundation and Collection | Limited Partner | Minority | ||
| Denmark's Export and Investment Fund | Venture Capital | Minority | ||
| The ATP Group | Limited Partner | Minority | ||
| The Growth Fund | PE/Buyout | Minority |
Visiopharm Acquisitions (2)
Visiopharm’s most recent deal was a Merger/Acquisition with LRI Imaging. The deal was made on 01-Dec-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LRI Imaging | 01-Dec-2016 | Merger/Acquisition | Other Devices and Supplies | ||
| Digital Pathology Consultants | 08-Dec-2012 | Merger/Acquisition | Consulting Services (B2B) |
Visiopharm Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| LRI Imaging | Lund, Sweden | 1971 |
Visiopharm FAQs
-
When was Visiopharm founded?
Visiopharm was founded in 2001.
-
Where is Visiopharm headquartered?
Visiopharm is headquartered in Hoersholm, Denmark.
-
What is the size of Visiopharm?
Visiopharm has 96 total employees.
-
What industry is Visiopharm in?
Visiopharm’s primary industry is Decision/Risk Analysis.
-
Is Visiopharm a private or public company?
Visiopharm is a Private company.
-
What is the current valuation of Visiopharm?
The current valuation of Visiopharm is .
-
What is Visiopharm’s current revenue?
The current revenue for Visiopharm is .
-
How much funding has Visiopharm raised over time?
Visiopharm has raised $29.2M.
-
Who are Visiopharm’s investors?
BankInvest Group, C. L. David Foundation and Collection, Denmark's Export and Investment Fund, The ATP Group, and The Growth Fund are 5 of 6 investors who have invested in Visiopharm.
-
Who are Visiopharm’s competitors?
Aiforia, Orchard Software, Ibex Medical Analytics, Kanteron Systems, and NovoPath are some of the 12 competitors of Visiopharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
